Cheng Feng, Wang Xue-Hao, Zhang Feng, Li Xiang-Cheng, Li Guo-Qiang, Sun Bei-Cheng, Kong Lian-Bao
Liver Transplantation Center, First Hospital of Nanjing Medical University, Key Laboratory of Living Donor Liver Transplantation, Ministry of Public Health, Nanjing 210029, China.
Zhonghua Wai Ke Za Zhi. 2009 Mar 15;47(6):437-40.
To probe into indication of living-related liver transplantation (LRLT) for Wilson's Disease.
From January 2001 to February 2007, thirty-seven living-related liver transplants were performed. A retrospective analysis was carried on outcome of those patients. The indications for LRLT were acute hepatic failure in 3 patients and chronic advanced liver disease in 32 patients including 13 patients with Wilsonian neurological manifestations. Two patients presented with severe Wilsonian neurological manifestations even though their liver functions were stable. According to the scoring system for evaluation of the neurological impairment in Wilson disease based on neurological signs and functions (total score was 30), the pre-transplantation score of those patients with neurological manifestations was 15.9 +/- 4.3 (n = 15).
Thirty-seven patients were followed up for 20 - 93 months. The survival rates of post-transplant patients and grafts at 1, 3, and 5 year were 91.9%, 83.8%, 75.7%, and 86.5%, 78.4%, 75.7%, respectively. Postoperative surgical complications occurred in 2 donors with bile leakage required drainage, in 2 recipients with hepatic thrombosis underwent retransplantation of cadaveric liver and in 1 recipient with hepatic stenosis required balloon dilatation. Neurological function was improved in all recipients and the score of posttransplantation at 6, 12, 18, 24, and 30 month was 17.5 +/- 3.7 (n = 13); 21.0 +/- 4.3 (n = 12); 23.9 +/- 3.9 (n = 10); 26.6 +/- 2.2 (n = 10) and 28.1 +/- 1.9 (n = 7) respectively.
Patients with acute hepatic failure or patients with severe liver disease unresponsive to chelation treatment should be treated with LRLT. Early transplantation in patients with an unsatisfactory response medical treatment may prevent irreversible neurological deterioration even though their liver function is stable.
探讨亲属活体肝移植(LRLT)治疗威尔逊病的适应证。
2001年1月至2007年2月,实施了37例亲属活体肝移植。对这些患者的结局进行回顾性分析。LRLT的适应证为3例急性肝衰竭患者和32例慢性晚期肝病患者,其中13例有威尔逊病神经系统表现。2例患者尽管肝功能稳定,但出现严重的威尔逊病神经系统表现。根据基于神经体征和功能的威尔逊病神经功能损害评估评分系统(总分30分),有神经系统表现的患者移植前评分为15.9±4.3(n = 15)。
37例患者随访20 - 93个月。移植后患者和移植物1年、3年和5年生存率分别为91.9%、83.8%、75.7%和86.5%、78.4%、75.7%。术后手术并发症发生在2例供体,胆汁漏需引流;2例受体肝血栓形成,接受尸体肝再移植;1例受体肝狭窄需球囊扩张。所有受体神经功能均有改善,移植后6个月、12个月、18个月、24个月和30个月的评分分别为17.5±3.7(n = 13);21.0±4.3(n = 12);23.9±3.9(n = 10);26.6±2.2(n = 10)和28.1±1.9(n = 7)。
急性肝衰竭患者或对螯合治疗无反应的严重肝病患者应接受亲属活体肝移植治疗。即使肝功能稳定,对药物治疗反应不佳的患者早期移植可预防不可逆的神经功能恶化。